Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azento is a macrolide antibiotic containing azithromycin as its active pharmaceutical ingredient. It is primarily used to treat a wide range of bacterial infections, including respiratory tract infections (such as bronchitis, pneumonia, sinusitis, tonsillitis, and pharyngitis), skin and soft tissue infections, otitis media, and sexually transmitted infections like gonorrhea. The drug exerts its antibacterial effect by binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting RNA-dependent protein synthesis and preventing bacterial growth. It is available in oral tablet formulations of 250mg and 500mg and is manufactured by companies such as Alkem Laboratories.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Azento.